Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Paratek Pharmaceuticals, Inc. | d272915dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
December 21, 2011 (December 21, 2011)
Date of Report (date of earliest event reported)
TRANSCEPT PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
| Delaware |
000-51967 |
33-0960223 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
1003 W. Cutting Blvd., Suite #110
Point Richmond, California 94804
(Address of principal executive offices)
(510) 215-3500
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other events. |
On December 21, 2011, Transcept Pharmaceuticals, Inc. (“Transcept”) issued a press release announcing receipt of a $10 million milestone payment from Purdue Pharma L.P. for listing Intermezzo® formulation patents in the U.S. Food and Drug Administration Orange Book. The full text of the press release is furnished herewith as Exhibit 99.1.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit No. |
Description | |
| 99.1 | Press release announcing receipt of $10 Million Milestone Payment from Purdue, dated December 21, 2011 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TRANSCEPT PHARMACEUTICALS, INC. | ||||||
| Date: December 21, 2011 | ||||||
| By: | /s/ Marilyn E. Wortzman | |||||
| Name: Marilyn E. Wortzman | ||||||
| Title: Vice President, Finance | ||||||
-2-
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Press release announcing receipt of $10 Million Milestone Payment from Purdue, dated December 21, 2011 | |
-3-